Ji Ping sold $83K of ANL

Ji Ping sold 5,000 shares of Adlai Nortye Group Ltd. (ANL) at $16.63 on 2026-09-22.

Original reporting
SEC EDGAR · Ji Ping
Published Sep 24, 2026, 3:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 3:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANL
Bearish
medium confidence
Mentioned
$ANL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANLBearishLow
01

Why it matters

The disclosed sale reduces the director's ownership, which may be interpreted by the market as a lack of confidence, though the amount is relatively small.

02

Market read

A modest insider sale; likely limited price impact unless followed by further insider activity.

03

What to watch

Potential tax planning or liquidity needs for the director.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions and are primary sources for such activity.

Company-level read

Ticker impact

$ANLBearishMedium confidence
Context

Director Ji Ping sold 5,000 shares for $83,150, reducing his stake to 131,667 shares.

Expected impact

Possible modest dip in ANL price over the next few days.

Evidence & confidence

Sale size is modest ($83k) but involves a director, which can influence market perception.

Market effects

Minimal impact on the broader sector; only reflects a single insider transaction.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be routine portfolio diversification, not a negative signal.

Key entities

  • Ji Ping

    Insider who sold shares of ANL.

  • Adlai Nortye Group Ltd.

    Issuer of the shares sold.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANLMed

Adlai Nortye collaborates with Lilly and Merck KGaA

Adlai Nortye Group (Nasdaq: ANL) has partnered with Eli Lilly (NYSE: LLY) and Merck KGaA (MRK: DE) for clinical trials involving cetuximab (Erbitux). The collaboration supports Adlai Nortye's Phase I trial for AN4035, evaluating it as a monotherapy and with cetuximab in specific cancer patients. The trial is sponsored by Adlai Nortye.

$ANLMed

Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial

Adlai Nortye (ANL) partnered with Lilly (LLY) and Merck KGaA for a trial of its cancer drug AN4035. Lilly and Merck will supply cetuximab for free in the US, Australia, and China. AN4035 targets colorectal, pancreatic, and lung cancers. ANL's stock is down 25.96% over 20 days, closing at $11.61 on the announcement day.